Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients

Nutrition Journal

Volumn 14, Issue 1, 2015, Pages

  Rahman, Inayat U ^a   Khan, Rooh Ullah ^b   Rahman, Khalil Ur ^b   Bashir, Mohammad ^c  

^a GANDHARA UNIVERSITY   (Pakistan)

^b Bannu Medical College   (Pakistan)

^c KIMS   (Pakistan)

Author keywords

Bitter melon; Cardiovascular risk factors; Glibenclamide; Glycemic control; Type 2 diabetics

Indexed keywords

GLIBENCLAMIDE; GLYCOSYLATED HEMOGLOBIN; MOMORDICA CHARANTIA EXTRACT; SIALIC ACID; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN; N ACETYLNEURAMINIC ACID;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOMORDICA CHARANTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; ATHEROSCLEROSIS; BIOASSAY; BLOOD; BLOOD PRESSURE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DIET THERAPY; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; METABOLISM; PHYTOTHERAPY;

CUCUMIS; EQUUS ASINUS;

ADULT; AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MOMORDICA CHARANTIA; N-ACETYLNEURAMINIC ACID; PHYTOTHERAPY;

EID: 85017330256     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-14-13     Document Type: Article

References (34)

1. Lambert J, Srivastava J, Vietmeyer N World Bank Technical Paper No. 355. In Medicinal plants: rescuing a global heritage. 1818 H Street, N.W. Washington, D.C. 20433, U.S.A; 1997.
2. Rizvi SI, Mishra N: Traditional Indian medicines used for the management of diabetes Mellitus. J Diab Res 2013. doi:10.1155/2013/712092
3. Bodeker G, Kronenberg F: A Public health agenda for traditional, complementary, and alternative medicine. Am J Publ Health 2002, 92:1582-91. 10.2105/AJPH.92.10.1582
4. Garau C, Cummings E, David AP, Jaipaul S: Beneficial effect and mechanism of action of Momordica charantia in the treatment of diabetes mellitus: a mini review. Int J Diab Metabol 2003, 11:46-55.
5. Abascal K, Yarnell E: Using bitter melon to treat diabetes. J Altern Complement Med 2005, 1:179-84.
6. Cummings E, Hundal HS, Wackerhage H, Hope M, Belle M, Adeghate E, et al.: Momordica Charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Mol Cell Biochem 2004, 261:99-104.
7. Akhtar N, Khan BA, Majid A, Khan S, Mahmood T: Pharmaceutical and biopharmaceutical evaluation of extracts from different plant parts of indigenous origin for their hypoglycemic responses in rabbits. Acta Pol Pharm 2011,68(6):919-25.
8. Ahmed I, Cummings E, Sharma AK, Adeghate E, Singh J: Beneficial effects and mechanism of action of Momordica Charantia fruit juice in the treatment of streptozotocin-induced diabetes mellitus in rats. Mol Cell Biochem 2004, 261:63-70.
9. Singh N, Gupta M, Sirohi P: Varsha: Effects of alcoholic extract of Momordica Charantia (Linn.) whole fruit powder on the pancreatic islets of alloxan diabetic albino rats. J Environ Biol 2008,29(1):101-6.
10. Ojewole JA, Adewole SO, Olayiwola G: Hypoglycemic and hypotensive effects of Momordica Charantia Linn. (Cucurbitaceae) whole plant aqueous extract in rats. Cardiovasc 2006, 17:227-32.
11. Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK: Antihyperglycemic effects of three extracts from Momordica Charantia. J Ethnopharmacol 2003, 88:107-11. 10.1016/S0378-8741(03)00184-3
12. Shibib BA, Khan LA, Rahman R: Hypoglycemic activity enzymes glucose-6-phosphatase and fructose-1-6-bisphosphatase and elevation of both liver and red cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem J 1993, 292:267-720.
13. Uebanso T, Arai H, Taketani Y, Fukaya M, Yamamoto H, Mizuno A, et al.: Extracts of Momordica Charantia suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol 2007,53(6):482-6. 10.3177/jnsv.53.482
14. Jeong J, Lee S, Hue J, Lee K, Nam SY, Yun YW, et al.: Effect of bitter melon on antidiabetic activity in C57 BL/6J db/db mice. Korean J Vet Res 2008,48(3):327-36.
15. Abdollah M, Zuki ABZ, Goh YM, Rezaeizadeh A, Noordin MM: The effects of bitter melon on the liver in STZ induced diabetes in neonatal rats. Afr J Biotechnol 2010,9(31):5004-12.
16. Singh J, Cumming E, Manoharan G, Kalasz H, Adeghate E: Medicinal chemistry of the antidiabetic effect of Momordica Charantia: active constituents and modes of action. Open Med Chem J 2011, 5:70-7. 10.2174/1874104501105010070
17. Nerurkar PV, Lee YK, Nerurkar VR: Bitter melon inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med 2010, 10:34. 10.1186/1472-6882-10-34
18. Gadang V, Gilbert W, Hettiararchchy N, Horax R, Katwa L, Devareddy L: Dietary bitter melon seed increases peroxisome proliferator activated receptor γ-gene expression in adipose tissue, down regulates the nuclear factor-kB expression and alleviates the symptoms associated with metabolic syndrome. J Med Food 2011, 14:86-93. 10.1089/jmf.2010.0010
19. Wehash FE, Abpo-Ghanema II, Saleh RM: Some physiological effects of Momordica Charantia and Trigonella foenum-graecum extracts in diabetic rats as compared with cidophage®. Proc World Acad Sci Eng Tech 2012, 64:1206-14.
20. Ahmad N, Hassan MR, Halder H, Bennoor KS: Effect of Momordica Charantia (Karella) extracts on fasting and postprandial serum glucose in NIDDM patients. Bangladesh Med Res Counc Bull 1999, 25:11-3.
21. Srivastava Y, Venkatakrishna BH, Verma Y, Venkaiah K, Raval BH: Antidiabetic and adaptogenic properties of Momordica Charantia extract: An experimental and clinical evaluation. Phytother Res 1993,7(4):285-9. 10.1002/ptr.2650070405
22. Fuangchan A, Sonthisombat P, Seubnukarn T, Chanouan R, Chotchaisuwat P, Sirigulsatien V, et al.: Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharm 2011, 134:422-8. 10.1016/j.jep.2010.12.045
23. Thaker A, Barton A: Multicultural handbook of Food, Nutrition and Dietetics. 9600 Garsington Road, Oxford, OX4 2DQ, UK: Willey Blackwell; 2012:27-8.
24. Pitipanapong J, Chitprasert S, Goto M, Jiratchariyakul W, Sasaki M, Shotipruk A: New approach for extraction of charantin from Momordica Charantia with pressurized liquid extraction. Sep Purif Technol 2007,52(3):416. 10.1016/j.seppur.2005.11.037
25. Zhi Xiang N, Chua KH, Kuppusamy UR: Proteomic analysis of heat treated bitter gourd (Momordica Charantia L. var. Hong Kong Green) using 2D-DIGE. Food Chem 2014, 148:155-61.
26. Tongia A, Tongia SK, Dave M: Phytochemicalm determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian J Physiol Pharmacol 2004,48(2):241-4.
27. Dans AM, Villarruz MV, Jimeno CA, Javelosa MA, Chua J, Bautista R, et al.: The effect of Momordica Charantia capsule preparation on glycemic control in type2 diabetes mellitus needs further studies. J Clin Epidemiol 2007, 60:554-9. 10.1016/j.jclinepi.2006.07.009
28. Crook MA, Tutt P: Serum sialic acid concentration in patients with hypertriglyceridemia showing the Frederickson IIb phenotype. Clin Sci 1992, 83:593-5.
29. Pickup JC, Mattock MB, Crook MA, Chusney GD, Burt D, Fitzgerald AP: Serum sialic acid concentration and coronary heart disease in NIDDM. Diabetes Care 1995,18(8):1100-3. 10.2337/diacare.18.8.1100
30. Knuiman MW, Watts GF, Divitini ML: Is sialic acid an independent risk factor for cardiovascular disease. A 17 year follow-up study in Busselton, Western Australia. Ann Epidemiol 2004, 14:627-32. 10.1016/j.annepidem.2003.09.017
31. Gokmen SS, Kilicli G, Folsom AR, Ozeelik F, Ture M, Gulen S: Association between serum total and lipid bound sialic acid concentration and the severity of coronary atherosclerosis. J Lab Clin Med 2002, 140:110-8. 10.1016/S0022-2143(02)00025-2
32. Tayyab F, Lal SS, Mishra M, Kumar U: Medicinal plants and its impact on diabetes. World J Pharmaceutical Res 2012,1(4):1019-46.
33. Laakso M: Morbidity and mortality in NIDDM: lipoproteins and coronary heart disease in NIDDM. J Diabetes Complications 1997, 11:137-41. 10.1016/S1056-8727(96)00092-X
34. Mahmood SS, Levy D, Vasan RS, Wang TJ: The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 2014,383(9921):999-1008. 10.1016/S0140-6736(13)61752-3